Biogen’s BIIB112 (cotoretigene toliparvovec) Fails to Meet its Primary Endpoint in P-II/III XIRIUS Study for XLRP

 Biogen’s BIIB112 (cotoretigene toliparvovec) Fails to Meet its Primary Endpoint in P-II/III XIRIUS Study for XLRP

Biogen’s BIIB112 (cotoretigene toliparvovec) Fails to Meet its Primary Endpoint in P-II/III XIRIUS Study for XLRP

Shots:

  • The P-II/III XIRIUS study involves assessing subretinal injection of cotoretigene toliparvovec in males with a genetically confirmed diagnosis of XLRP. Part 1 of the study was a 24mos. dose-escalation study while part II was a 12mos. dose expansion study with a high & low dose selected from part I based on a benefit/risk assessment
  • The study failed to meet its 1EPs demonstrating improvement in the proportion of treated study eyes with ≥7 dB improvement from baseline at ≥5 of the 16 central loci of the 10-2 grid assessed by MAIA microperimetry
  • BIIB112 is an investigational AAV8 vector-based gene therapy to provide full-length functioning RPGR protein in patients with XLRP

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Stat News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post